Detalles de la búsqueda
1.
Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade.
Immunity
; 50(2): 477-492.e8, 2019 02 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-30737146
2.
Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition.
Gut
; 71(7): 1277-1288, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34433583
3.
A Potent and Effective Suicidal Listeria Vaccine Platform.
Infect Immun
; 87(8)2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31235641
4.
Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers.
Gynecol Oncol
; 154(2): 314-322, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31204078
5.
Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma.
J Neurooncol
; 140(2): 317-328, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-30073642
6.
Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.
Proc Natl Acad Sci U S A
; 109(16): 6187-92, 2012 Apr 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-22474386
7.
Augmented IL-15Rα expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice.
J Immunol
; 188(12): 6156-64, 2012 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22593619
8.
Platinum ineligibility and survival outcomes in patients with advanced urothelial carcinoma receiving first-line treatment.
J Natl Cancer Inst
; 116(4): 547-554, 2024 Apr 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38036464
9.
CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy.
Cell Rep Med
; 4(1): 100878, 2023 01 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-36599350
10.
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade.
Proc Natl Acad Sci U S A
; 105(9): 3509-14, 2008 Mar 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-18303116
11.
Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study.
Clin Cancer Res
; 27(12): 3360-3369, 2021 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33568344
12.
Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer.
Clin Lung Cancer
; 21(5): 455-463.e4, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32586767
13.
Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab.
J Immunother Cancer
; 7(1): 274, 2019 10 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-31647026
14.
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab.
Clin Cancer Res
; 25(20): 6061-6072, 2019 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31358540
15.
Association of Cancer Immunotherapy With Acute Macular Neuroretinopathy and Diffuse Retinal Venulitis.
JAMA Ophthalmol
; 137(1): 96-100, 2019 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30383154
16.
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.
JAMA Oncol
; 5(1): 74-82, 2019 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30242306
17.
Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study.
JAMA Oncol
; 4(4): 537-544, 2018 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29423515
18.
Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study.
Eur J Cancer
; 101: 201-209, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30077125
19.
Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.
J Clin Oncol
; 34(8): 833-42, 2016 Mar 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-26755520
20.
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab-Response.
Clin Cancer Res
; 26(10): 2436, 2020 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32414763